U
Morphic Medical, Inc. GIDYL
OTC PK
Recommendation
--
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
--
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

03/31/2021 12/31/2020 09/30/2020 06/30/2020 03/31/2020
Net Income 40.23% -- -- -- --
Total Depreciation and Amortization -4.55% -- -- -- --
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items -68.20% -- -- -- --
Change in Net Operating Assets -26.43% -- -- -- --
Cash from Operations 10.06% -- -- -- --
Capital Expenditure -- -- -- -- --
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions -- -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities -- -- -- -- --
Cash from Investing -- -- -- -- --
Total Debt Issued -80.98% -- -- -- --
Total Debt Repaid -- -- -- -- --
Issuance of Common Stock -- -- -- -- --
Repurchase of Common Stock -- -- -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities -- -- -- -- --
Cash from Financing -50.47% -- -- -- --
Foreign Exchange rate Adjustments -- -- -- -- --
Miscellaneous Cash Flow Adjustments -- -- -- -- --
Net Change in Cash -213.82% -- -- -- --
Weiss Ratings